JP7527207B2 - ナチュラルキラー細胞 - Google Patents

ナチュラルキラー細胞 Download PDF

Info

Publication number
JP7527207B2
JP7527207B2 JP2020571746A JP2020571746A JP7527207B2 JP 7527207 B2 JP7527207 B2 JP 7527207B2 JP 2020571746 A JP2020571746 A JP 2020571746A JP 2020571746 A JP2020571746 A JP 2020571746A JP 7527207 B2 JP7527207 B2 JP 7527207B2
Authority
JP
Japan
Prior art keywords
cells
rev
compound
erb
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020571746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528969A (ja
Inventor
マシュー ジェー． フックター
アマイア ウリス ウアルテ
ヒュー ジェー．エム． ブレディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of JP2021528969A publication Critical patent/JP2021528969A/ja
Priority to JP2024065848A priority Critical patent/JP2024095819A/ja
Application granted granted Critical
Publication of JP7527207B2 publication Critical patent/JP7527207B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020571746A 2018-06-26 2019-06-26 ナチュラルキラー細胞 Active JP7527207B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024065848A JP2024095819A (ja) 2018-06-26 2024-04-16 ナチュラルキラー細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1810486.9 2018-06-26
GBGB1810486.9A GB201810486D0 (en) 2018-06-26 2018-06-26 Natural killer cells
PCT/GB2019/051803 WO2020002911A1 (en) 2018-06-26 2019-06-26 Natural killer cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024065848A Division JP2024095819A (ja) 2018-06-26 2024-04-16 ナチュラルキラー細胞

Publications (2)

Publication Number Publication Date
JP2021528969A JP2021528969A (ja) 2021-10-28
JP7527207B2 true JP7527207B2 (ja) 2024-08-02

Family

ID=63042803

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571746A Active JP7527207B2 (ja) 2018-06-26 2019-06-26 ナチュラルキラー細胞
JP2024065848A Pending JP2024095819A (ja) 2018-06-26 2024-04-16 ナチュラルキラー細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024065848A Pending JP2024095819A (ja) 2018-06-26 2024-04-16 ナチュラルキラー細胞

Country Status (8)

Country Link
US (1) US12377119B2 (https=)
EP (1) EP3814485A1 (https=)
JP (2) JP7527207B2 (https=)
CN (1) CN112752837A (https=)
AU (1) AU2019293163B2 (https=)
CA (1) CA3104674A1 (https=)
GB (1) GB201810486D0 (https=)
WO (1) WO2020002911A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024095819A (ja) * 2018-06-26 2024-07-10 インペリアル・カレッジ・イノベーションズ・リミテッド ナチュラルキラー細胞

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201703476D0 (en) 2017-03-03 2017-04-19 Imp Innovations Ltd Natural killer cells
AU2021372389A1 (en) * 2020-10-16 2023-05-11 Pelagos Pharmaceuticals, Inc. Rev-erb agonists
WO2024047368A1 (en) 2022-09-02 2024-03-07 Imperial College Innovations Limited Natural killer cells
GB202217507D0 (en) 2022-11-23 2023-01-04 Imperial College Innovations Ltd Natural killer cells
AU2024212529A1 (en) * 2023-01-27 2025-06-19 Opna Bio SA Compounds and methods for yap/tead modulation and indications therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536364A (ja) 1999-02-04 2002-10-29 エス ケー コーポレイション テトラヒドロイソキノリンアルカノール誘導体及びそれを含む薬学的組成物
WO2013033310A1 (en) 2011-08-31 2013-03-07 Theodore Mark Kamenecka Modulators of rev-erb
WO2015103527A1 (en) 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
JP2016187341A (ja) 2009-12-29 2016-11-04 ガミダ セル リミテッド エクスビボ培養されたナチュラルキラー細胞の集団
JP7225107B2 (ja) 2017-03-03 2023-02-20 インペリアル・カレッジ・イノベーションズ・リミテッド ナチュラルキラー細胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59141562A (ja) * 1983-02-01 1984-08-14 Nippon Kayaku Co Ltd Ｎ，ｎ′−置換イミダゾ−ルカルボキサミド誘導体および農園芸用殺菌殺線虫剤
JPS60109568A (ja) * 1983-11-17 1985-06-15 Ube Ind Ltd イミダゾ−ル誘導体および農園芸用殺菌剤
GB9206757D0 (en) * 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
AU5845096A (en) * 1995-05-31 1996-12-18 Nissan Chemical Industries Ltd. 5-pyrazolecarboxamide derivatives and plant disease control agent
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
WO2003000657A1 (en) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
EP1442028A4 (en) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
BR0312503A (pt) * 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
US20090062212A1 (en) 2007-05-07 2009-03-05 Elliott Richelson Peptide analogs that are potent and selective for human neurotensin preceptor subtype 2
CA3080368A1 (en) * 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
WO2012075412A1 (en) * 2010-12-03 2012-06-07 Michael Verneris Generation of natural killer cells and lymphoid tissue inducer-like (lti-like) nk-22 cells
WO2012128622A1 (en) 2011-03-18 2012-09-27 Ipd-Therapeutics B.V. Generation of nk cells and nk-cell progenitors
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
CN103710304B (zh) * 2012-09-29 2018-11-02 北京东方百奥医药开发有限公司 脂肪干细胞诱导分化为自然杀伤细胞的方法及用途
ITTO20130816A1 (it) * 2013-10-09 2015-04-10 Fond Istituto Italiano Di Tecnologia Antagonisti di rev-erb diarilalchilaminici e loro uso come farmaci
GB201704953D0 (en) * 2017-03-28 2017-05-10 Imp Innovations Ltd Natural killer cells
WO2018178663A1 (en) * 2017-03-30 2018-10-04 Parker Hannifin Manufacturing Limited A pressure swing adsorption system with a variable flow restrictor
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536364A (ja) 1999-02-04 2002-10-29 エス ケー コーポレイション テトラヒドロイソキノリンアルカノール誘導体及びそれを含む薬学的組成物
JP2016187341A (ja) 2009-12-29 2016-11-04 ガミダ セル リミテッド エクスビボ培養されたナチュラルキラー細胞の集団
WO2013033310A1 (en) 2011-08-31 2013-03-07 Theodore Mark Kamenecka Modulators of rev-erb
WO2015103527A1 (en) 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
JP7225107B2 (ja) 2017-03-03 2023-02-20 インペリアル・カレッジ・イノベーションズ・リミテッド ナチュラルキラー細胞

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Angew. Chem. int. Ed.，2015年，Vol.54，p.12389-12393
Biol Blood Marrow Transplant，2009年，vol.15，p.1026-1037
Chimika chronika, New Series，1989年，Vol.18，p.3-17
nature immunology，2009年，vol.10, no.10，p.1118-1124
比較内分泌学，2010年，Vol.36，p.118-126

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024095819A (ja) * 2018-06-26 2024-07-10 インペリアル・カレッジ・イノベーションズ・リミテッド ナチュラルキラー細胞

Also Published As

Publication number Publication date
JP2021528969A (ja) 2021-10-28
US20220073880A1 (en) 2022-03-10
AU2019293163B2 (en) 2025-10-23
CA3104674A1 (en) 2020-01-02
WO2020002911A1 (en) 2020-01-02
AU2019293163A1 (en) 2021-01-21
JP2024095819A (ja) 2024-07-10
CN112752837A (zh) 2021-05-04
EP3814485A1 (en) 2021-05-05
GB201810486D0 (en) 2018-08-08
US12377119B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
JP7527207B2 (ja) ナチュラルキラー細胞
JP6214643B2 (ja) ピリミジニルチロシンキナーゼ阻害剤
JP2024029182A (ja) γｃサイトカイン活性を調節するための組成物および方法
JP2022532247A (ja) Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用
JP7458336B2 (ja) γｃサイトカイン活性の調節
CN107206085B (zh) 使用α9整联蛋白拮抗剂和CXCR4拮抗剂的HSC的迁移和释放
EP4301755A1 (en) Combination of a t cell therapy and a dgk inhibitor
EP3807261B1 (en) Pyridinyl pyrazoles as modulators of roryt
UA128864C2 (uk) Сполука пладієноліду та спосіб її застосування
CN110709507A (zh) 自然杀伤细胞
CN102596904B (zh) 蛋白酶抑制剂、组合物及使用方法
KR102547762B1 (ko) 신규 화합물 및 이의 자가면역질환 치료 용도
TWI354664B (en) Cyclic derivatives as modulators of chemokine rece
CN120693400A (zh) 自然杀伤细胞
WO2018176034A1 (en) Modulators of notch signaling and methods of use thereof
US20170348375A1 (en) Dislodgement and release of hsc from the bone marrow stem cell niche using alpha9 integrin antagonists
CN110494136A (zh) 细胞保护性化合物及其用途
JP2025531850A (ja) Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
EA051741B1 (ru) Композиции и способы модулирования активности короткоцепочечной дегидрогеназы

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230825

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240723

R150 Certificate of patent or registration of utility model

Ref document number: 7527207

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150